Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: A single center experience.

Simple item page
dc.contributor.authorSingh, Neha
dc.contributor.authorSazawal, Sudha
dc.contributor.authorUpadhyay, Ashish
dc.contributor.authorChhikara, Sunita
dc.contributor.authorMahapatra, Manoranjan
dc.contributor.authorSaxena, Renu
dc.date.accessioned2015-06-29T07:30:05Z
dc.date.available2015-06-29T07:30:05Z
dc.date.issued2015-04
dc.description.abstractIntroduction: Somatic mutation in the exon 14 of Janus Kinase 2 gene is an established diagnostic marker in bcr-abl negative myeloproliferative neoplasms, especially primary idiopathic myelofi brosis (PIMF). Aim: Our primary aim was to fi nd out the correlation between the JAK2V617F mutational status and the clinico-hematologic characteristics, as well as the international prognostic scoring system (IPSS) scoring of patients with PIMF. Materials and Methods: Clinical and hematologic features were reviewed for 68 patients with primary idiopathic myelofi brosis (PIMF). JAK2V617F mutation status was analyzed by amplifi cation refractory mutation screening-polymerase chain reaction. The patients were further stratifi ed into low, intermediate-1, intermediate-2 and high-risk groups on the basis of IPSS scoring. Results: The JAK2V617F mutation was detected in 58.8% patients. Univariate analysis of variables at presentation identifi ed that JAK2V617F negative patients were signifi cantly associated with more severe anemia (P = 0.045), younger age (P = 0.008), higher transfusion requirement (P = 0.017), and thrombocytopenia (P = 0.015). Patients who were homozygous for JAK2V617F mutation were associated with thrombocytosis (P = 0.014) and also had higher median total leucocyte count (P = 0.20) than the other groups. No signifi cant correlation was detected between JAK2V617F mutational status and the presence of constitutional symptoms, spleen size, grade of bone marrow fi brosis or prognostic risk stratifi cation of the PIMF patients. Conclusion: The variations in the prognostic implication of PIMF patients with mutation status as stated by various publications worldwide, reinstates the need for larger prospective studies using standardized JAK2V617F quantifi cation methods as well as estimation of other newer molecular markers to develop deeper insight into various molecular alterations involving PIMF patients in India as well as worldwide.en_US
dc.identifier.citationSingh Neha, Sazawal Sudha, Upadhyay Ashish, Chhikara Sunita, Mahapatra Manoranjan, Saxena Renu. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: A single center experience. Indian Journal of Pathology & Microbiology. 2015 Apr-Jun 58(2): 187-191.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/158584
dc.language.isoenen_US
dc.source.urihttps://www.ijpmonline.org/article.asp?issn=0377-4929;year=2015;volume=58;issue=2;spage=187;epage=191;aulast=Singhen_US
dc.subjectJanus Kinase 2 mutationen_US
dc.subjectpolymerase chain reactionen_US
dc.subjectprimary myelofi brosisen_US
dc.titleCorrelation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: A single center experience.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpm2015v58n2p187.pdf
Size:
544.61 KB
Format:
Adobe Portable Document Format
Description:
Original article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Pathology & Microbiology